Efficacy and safety of finerenone in diabetic kidney disease: Latin American experience from FINDKDLATAM trial

Figure 1 Distribution of prescribed nephroprotective regimens. This bar chart illustrates the frequency of different therapeutic combinations. Dual therapy consisting of renin-angiotensin-aldosterone system inhibitors and sodium-glucose cotransporter inhibitors was the most prevalent regimen (43.5%), highlighting the acceptance of combination therapy over monotherapies or other classes of drugs. RASSi: Renin-angiotensin-system inhibitors; SGLT2i: Sodium-glucose cotransporter inhibitor; GLP-1ra: Glucagon-like peptide-1 receptor agonist.

Figure 2 Changes in very high-risk stratification: Baseline vs final assessment. Comparison of the proportion of patients classified as very high risk at baseline (blue) vs the final visit (orange). The data demonstrates a statistically significant reduction (93.9% vs 85.7%; P = 0.0004), indicating a favorable shift in risk profile following the intervention period.